Drug Trial Radar · NCT00004414
Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis
Last checked: Nov 19, 2026Latest source record: Mar 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
252
Actual
Start
Sep 1997
Primary completion
Not stated
Study completion Jun 2002
Sponsor
- Lead sponsor
- University of MichiganAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 19, 1999
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 30 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OBJECTIVES: I. Compare conjugated bilirubin levels and serum bile acid levels in severely premature newborns on long term parenteral nutrition and given either sincalide or placebo. II. Compare morbidity and mortality rates in this patient population. III. Evaluate ultrasonographic images of the hepatobiliary tree during and 1 to 2 years after the administration of sincalide or placebo to assess the development of biliary sludge and biliary stone formation.
Conditions
- Cholestasis
Interventions
sincalideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Johns Hopkins Oncology Center
Baltimore, Maryland
University of Michigan Medical School
Ann Arbor, Michigan
University of Rochester Medical Center
Rochester, New York
Children's Hospital Medical Center - Cincinnati
Cincinnati, Ohio
Rhode Island Hospital
Providence, Rhode Island
Baylor University Medical Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.